SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

April 05, 2012 07:00 ET

Implant Sciences Hires Quality Manager to Prepare Company for Increased Production

WILMINGTON, MA--(Marketwire - Apr 5, 2012) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has hired Charles Fertitta as Quality Manager, reporting to Brenda Baron, Vice President of Manufacturing. Mr. Fertitta fills this newly created position to ensure adherence to the Company's stringent quality standards in anticipation of production volume growth.

Mr. Fertitta is a skilled hands-on Software Quality Assurance Engineer and Certified Software Tester. He has served as Senior Software Quality Assurance Engineer at both Reveal Imaging Technologies and PHT Corporation. Prior to those positions, he held several engineering, manufacturing, and quality assurance positions at L3 Communications Security and Detection Systems, including Quality Assurance Group Leader. Mr. Fertitta has a BS in Business Management from Franklin Pierce College.

"With the hiring of Charles Fertitta as Quality Manager, Andy Anderson as Director of Engineering, and Bill McGann as COO, Implant Sciences has added significant security industry experience to our management team. These three individuals greatly expand our ability to meet the needs of our growing customer base. We are pleased that talented engineers who have worked at security companies many times our size are joining Implant Sciences to help support our anticipated growth," stated Implant Sciences President and CEO Glenn D. Bolduc.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact